Drugs that contain Lusutrombopag

1. Drug name - MULPLETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(1 year, 11 months from now)

US8889722 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jul, 2028

(5 years from now)

US8530668 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jan, 2030

(7 years from now)

CN1863783A SHIONOGI INC Compound Having Thrombopoietin Receptor Agonist Activity
Jul, 2013

(9 years ago)

CN103393678A SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2016

(6 years ago)

CN102796058A SHIONOGI INC Compound Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

CN103130739B SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN102796058B SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN103130739A SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN101809008B SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

CN101809008A SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103450110B SHIONOGI INC Pharmaceutical Composition Containing An Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103396313A SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103450110A SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103396313B SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

IN232700B SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

IN200600512P4 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291B1 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291A1 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291A4 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP2184279A4 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

EP2184279A1 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

EP2184279B1 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402 SHIONOGI INC Preparation for improving solubility of poorly soluble drug Sep, 2031

(9 years from now)

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.